First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
The pilot plant is focused on scaling up beverage production and will support applications
To accelerate the development of next-generation radioconjugates to treat cancer
A five-day inspection was concluded successfully with no critical and no major observations raised
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Subscribe To Our Newsletter & Stay Updated
